Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)By Chris Markoch. Publication Date: 1/18/2026. 
What You Need to Know - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. That typically means targeting companies with disruptive technologies, exposure to emerging trends, or a compelling turnaround story. Many of these companies will never scale or survive, but if even one succeeds, investors can realize substantial gains. MarketBeat's tool lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. While popularity is no guarantee of success, it can provide additional conviction for investors evaluating a speculative idea. SpaceX just announced it is rapidly repositioning 4,400 Starlink satellites into lower Earth orbit. While the official explanation points to safety and debris concerns, the move comes days after China labeled Starlink a national security threat, raising serious questions about what's really happening behind the scenes.
If this escalation in space is an early warning signal, most investors won't react until markets already feel the impact. One analyst has updated his playbook for how to protect capital if geopolitical tensions accelerate. See the full briefing and his 3-step plan here Some investors define a penny stock as any share trading for $5 or less. This screener, however, uses the traditional definition — stocks priced below $1. These shares are highly volatile; conduct your own research and understand your risk tolerance before initiating a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart rests on its novel delivery approach. If the company secures FDA approval and successfully scales production, its oral vaccines could reduce logistical barriers to mass immunization and create opportunities for significant licensing partnerships. Positive trial results or a commercial collaboration could also sharply improve sentiment and valuation given the stock's current low base. Clinical risk is the primary challenge. Vaxart has not yet brought a product to market, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets further constrains visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. The MarketBeat analyst ratings show just a single analyst covering Vaxart, which is not uncommon for sub-$1 stocks but should signal caution to investors. The company has only 18% institutional ownership. On the positive side, short interest is low at roughly 2%, which may dampen some volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure and industrial sensing. The company's hardware and software solutions enable precise 3D mapping needed for self-driving and advanced driver-assistance systems (ADAS). Microvision is focused on creating compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision hinges on the ongoing push toward vehicle automation and the potential for partnerships with major automotive manufacturers. If the company can demonstrate superior performance or a clear cost advantage, it could secure supply agreements or licensing deals that materially improve revenue visibility. Microvision's technology may also find applications in robotics and smart-city infrastructure, adding optionality to its growth story. Still, Microvision faces intense competition from LiDAR players such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ) and Ouster (NYSE: OUST). The timeline to broad commercial adoption of LiDAR has repeatedly slipped, which has frustrated investors and keeps the path to profitability uncertain. MVIS is covered by three analysts and carries a consensus price target of $2.50, implying about a 169% gain from its Jan. 15 closing price. Like many speculative names, Microvision has relatively low institutional ownership (around 30%) and elevated short interest (around 21%), factors that contribute to potential volatility for long-term investors. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization and digital asset management. The company helps organizations turn raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities that many traditional systems overlook. The bullish thesis for Datavault AI centers on its niche focus and scalability potential. As data becomes an increasingly valuable commodity, businesses and individuals are seeking ways to securely monetize digital information. Datavault's technology could benefit from broader AI adoption and rising interest in data sovereignty. Early traction or strategic partnerships could catalyze investor confidence. That said, Datavault AI operates in a highly experimental space. The company's business model is still evolving, and its path to meaningful revenue growth remains unproven. Institutions own less than 1% of the stock, and short interest exceeds 16% as of this writing. Investors considering DVLT should treat it as a long-term, speculative position based on belief in the data-as-an-asset thesis rather than expectations of near-term earnings.
| 
